Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity of moderate to severe vasomotor symptoms due to menopause and patient-reported sleep disturbance at 24 weeks Women considered unsuitable included those with contraindications, who are averse to taking, have stopped taking or have conditions that suggest caution in using hormone therapy Results will support health technology a.
Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity.
Global Healthcare Leaders Advance Sector Decarbonisation Ahead Of COP28 menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
The surprising health benefits of praying the rosary in Latin catholicherald.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from catholicherald.co.uk Daily Mail and Mail on Sunday newspapers.